


Response to September 30, 2004 Office Action
Application No. 10/657,762
Attorney's Docket No. 02-166
Page 4

AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions and listing of claims in the application. For the convenience of the Examiner, a clean copy of the pending claims is attached as Appendix B.

1. (Original) A compound of the formula:



wherein:

- R is hydrogen or lower alkyl;
R¹ is optionally substituted lower alkoxy or optionally substituted cycloalkyloxy;
R² is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or trialkylsilyl; and
R³ is hydroxymethyl or R⁴R⁵NC(O)-, where R⁴ and R⁵ are independently chosen from hydrogen, optionally substituted alkyl or optionally substituted cycloalkyl.

2. (Original) The compound of claim 1, wherein R³ is hydroxymethyl.
3. (Original) The compound of claim 2, wherein R is hydrogen.
4. (Original) The compound of claim 3, wherein R¹ is methoxy, ethoxy, n-propoxy, isopropoxy, or cyclopropoxy.
5. (Original) The compound of claim 4, wherein R¹ is methoxy.

Response to September 30, 2004 Office Action
Application No. 10/657,762
Attorney's Docket No. 02-166
Page 5

6. (Original) The compound of claim 5, wherein R^2 is phenyl, namely (4S,2R,3R,5R)-5-(hydroxymethyl)-2-[6-(methoxyamino)-2-(2-phenylethynyl)purin-9-yl]oxolane-3,4-diol.
7. (Original) The compound of claim 5, wherein R^2 is 4-methylphenyl, namely (4S,2R,3R,5R)-5-hydroxymethyl-2-[6-(methoxyamino)-2-[(2(4-methylphenyl)ethynyl)]purin-9-yl]oxolane-3,4-diol.
8. (Original) The compound of claim 5, wherein R^2 is 4-fluorophenyl, namely (4S,2R,3R,5R)-2-{2-[2-4-fluorophenyl)ethynyl]-6-(methoxyamino)purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol.
9. (Currently amended) The compound of claim 5, wherein R^2 is 4-pentylphenyl, namely (4S,2R,3R,5R)-5-hydroxymethyl-2-{6-(methoxyamino)-2-[2-(4-pentylphenylethynyl)]purin-9-yl}oxolane-3,4-diol.
10. (Currently amended) The compound of claim 5, wherein R^2 is 3-trifluoromethylphenyl, namely, (4S,2R,3R,5R)-5-(hydroxymethyl)-2-[6-(methoxyamino)-2-[(2(3-trifluoromethyl)phenyl)ethynyl]purin-9-yl]oxolane-3,4-diol.
11. (Original) The compound of claim 5, wherein R^2 is 4-methoxyphenyl, namely (4S,2R,3R,5R)-5-(hydroxymethyl)-2-[6-(methoxyamino)-2-[(2(4-methoxyphenyl)ethynyl)]purin-9-yl]oxolane-3,4-diol.
12. (Original) The compound of claim 5, wherein R^2 is 4-cyanomethylphenyl, namely 6-{9-2-[4-(2-{9-[4S,2R,3R,5R]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(methoxyamino)-purin-2-yl}ethynyl)phenyl]ethanenitrile.
13. (Canceled)

Response to September 30, 2004 Office Action
Application No. 10/657,762
Attorney's Docket No. 02-166
Page 6

14. (Original) The compound of claim 5, wherein R^2 is butyl, namely (4S,2R,3R,5R)-2-{2-[2-hex-1-ynyl-6-methoxyamino]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol.
15. (Currently amended) The compound of claim 5, wherein R^2 is 2-hydroxypropyl, namely (4S,2R,3R,5R)-5-(hydroxymethyl)-2-[-2-(4-hydroxypent-1-ynyl)-6-(methoxyamino) purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol.
16. (Currently amended) The compound of claim 5, wherein R^2 is 2-hydroxycyclohexyl, namely (4S,2R,3R,5R)-5-(hydroxymethyl)-2-[-2-(2-hydroxycyclohexyl-1-ynyl)-6-(methoxyamino) purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol.
17. (Currently amended) The compound of claim 5, wherein R^2 is 2-pyridyl, namely (4S,2R,3R,5R)-5-(hydroxymethyl)-2-[6-(methoxyamino)-2-[(2-(2-pyridyl)ethynyl) purin-9-yl]oxolane-3,4-diol.
18. (Original) The compound of claim 1, wherein R^3 is $R^4R^5NC(O)-$.
19. (Original) The compound of claim 18, wherein R is hydrogen.
20. (Original) The compound of claim 19, wherein R^1 is methoxy.
21. (Original) The compound of claim 20, wherein R^4 is hydrogen and R^5 is methyl or ethyl.
22. (Original) The compound of claim 21, wherein R^2 is optionally substituted phenyl or optionally substituted pyridyl.

Response to September 30, 2004 Office Action

Application No. 10/657,762

Attorney's Docket No. 02-166

Page 7

23. (Original) The compound of claim 22, wherein R² is phenyl, 4-methylphenyl, 4-fluorophenyl, 3-trifluoromethylphenyl, 4-methoxyphenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl.

24. (Original) A method of treating a disease state by stimulating adenosine A₃ receptors, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of claim 1.

Claims 25 and 26. (Canceled)

27. (Original) A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of claim 1.

Claims 28-31. (Canceled)